Introduction
============

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related deaths worldwide ([@b1-ijo-50-02-0381],[@b2-ijo-50-02-0381]). The 5-year overall survival rate of HCC patients ranges from 0 to 14% ([@b3-ijo-50-02-0381]). Although patients frequently experience recurrence after curative resection, the therapeutic alternatives for advanced and recurrent HCC are limited compared with those available for managing other cancers of the digestive tract ([@b4-ijo-50-02-0381],[@b5-ijo-50-02-0381]). Therefore, it is important to identify new biomarkers for predicting outcomes as well as new molecular targets for treating HCC ([@b6-ijo-50-02-0381]).

Protein arginine methyltransferases (PRMTs) are the major enzymes that methylate arginine residues in histones ([@b7-ijo-50-02-0381]). There are four types of PRMTs, and *PRMT5* is a type II PRMT that catalyzes monomethylation and symmetric dimethylation reactions ([@b8-ijo-50-02-0381]--[@b10-ijo-50-02-0381]). Symmetric dimethylation of histones inhibits transcription, and inhibition of the expression of tumor suppressor genes causes tumorigenesis and the progression of cancer ([@b10-ijo-50-02-0381]--[@b12-ijo-50-02-0381]). *PRMT5* acts as an oncogene in some neoplasms through inhibition of the transcription of certain tumor suppressor genes, promotes cell proliferation, and inhibits apoptosis ([@b10-ijo-50-02-0381],[@b11-ijo-50-02-0381],[@b13-ijo-50-02-0381],[@b14-ijo-50-02-0381]). Moreover, *PRMT5* contributes to epithelial-mesenchymal transition through interactions with E-cadherin and affects RNA processing ([@b7-ijo-50-02-0381],[@b10-ijo-50-02-0381],[@b12-ijo-50-02-0381]). Zhang *et al* indicated that inhibition of *PRMT5* induced HCC cell growth via the downregulation of β-catenin ([@b15-ijo-50-02-0381]). However, little is known about the role of *PRMT5* in the pathogenesis of HCC. Therefore, the aim of this study was to investigate the expression and functions of *PRMT5* in HCC, and the results presented here lead us to propose that *PRMT5* is associated with HCC.

Materials and methods
=====================

Ethics
------

This study conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects and has been approved by the Institutional Review Board of Nagoya University, Japan. Written informed consent for usage of clinical samples and data, as required by the institutional review board, was obtained from all patients.

Sample collection
-----------------

The human HCC cell lines Hep3B, HepG2, PLC/PRF/5 and SK-Hep1 were purchased from the American Type Culture Collection (Manassas, VA, USA). HLE, HLF, HuH1 and HuH7 were obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan) ([@b16-ijo-50-02-0381]). HuH2 cells were a gift from Aichi Cancer Center (Nagoya, Japan). Cells were stored at −80°C and cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS) at 37°C in an atmosphere containing 5% CO~2~. Primary HCC tissues and corresponding noncancerous tissues appropriate for extraction of total RNA were collected from 144 patients undergoing liver resection for HCC at Nagoya University Hospital between January 1998 and January 2012. None of the patients underwent preoperative treatment including chemotherapy or interventional radiology. Tissue samples were frozen immediately in liquid nitrogen and stored at −80°C. RNA was extracted from HCC tissue samples \~5-mm^2^ that contained \>80% tumor cells and lacked necrotic tissue ([@b17-ijo-50-02-0381],[@b18-ijo-50-02-0381]). The corresponding noncancerous tissue samples were collected from areas \>2 cm away from the tumor edge. Specimens were classified histologically according to the TNM Classification of Malignant Tumors, 7th Edition ([@b19-ijo-50-02-0381]). Clinicopathological parameters and the patient follow-up data were collected from medical records.

Quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR)
--------------------------------------------------------------------------------

*PRMT5* mRNA levels were determined using qRT-PCR. Total RNAs (10 *μ*g) were extracted from nine HCC cell lines and 144 pairs of clinical samples and were amplified using primers specific for *PRMT5* as follows: sense 5′-TCTCATGGTTTCCCATCCTC-3′ in exon 16 and antisense 5′-CCTTCTTGGAATTGCTGCAT-3′ in exon 17, which generate a 102-bp product. Glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) mRNA (TaqMan, *GAPDH* control reagents; Applied Biosystems, Foster City, CA, USA) was quantified in each sample for standardization. qRT-PCR was performed using the SYBR-Green PCR Core reagents kit (Applied Biosystems) as follows: one cycle at 95°C for 10 min, 40 cycles at 95°C for 5 sec, and 60°C for 60 sec. The expression levels of each sample were determined in triplicate, and the data are presented as the *PRMT5* value divided by the GAPDH value ([@b20-ijo-50-02-0381],[@b21-ijo-50-02-0381]). Patients were stratified into *PRMT5*-low and *PRMT5*-high groups, respectively, according to the median value of the *PRMT5* mRNA expression level in cancer tissues of 144 patients as follows: high (higher than the median value) and low (the median value or lower).

Immunofluorescence staining
---------------------------

The expression and location of PRMT5 protein was investigated by immunofluorescence staining using three HCC cell lines, Hep3B, HLE and HuH7, expressed relatively high levels of PRMT5. HCC cells were fixed on microscope slides by methanol. Slides were cooled at −10°C for 5 min and incubated with mouse monoclonal antibody raised against PRMT5 (sc-376937 FITC; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), diluted 1:50 in phosphate-buffered saline (PBS). The nuclei were counter-stained with 1 *μ*g/ml DAPI. The slides were observed under a fluorescence microscope, FSX100 (Olympus, Tokyo, Japan).

Western blot analysis
---------------------

Cells were incubated in RIPA lysis buffer, and the lysates were stored at −30°C. Total lysate protein (15 *μ*g/well) was electrophoretically transferred onto nitrocellulose membranes that were blocked using 5% skim milk and incubated at 4°C overnight with a rabbit anti-*PRMT5* polyclonal antibody (Cell Signaling Technology, Beverly, MA, USA) diluted 1:1,000. The membrane was then washed and probed with an anti-rabbit secondary antibody conjugated to horseradish peroxidase (Cell Signaling Technology). After the final wash, immune complexes were visualized using an LAS-4010 image analyzer (GE Healthcare, Pittsburgh, PA, USA). β-actin served as an endogenous control ([@b22-ijo-50-02-0381]).

Knockdown of PRMT5 expression using a PRMT5-specific siRNA
----------------------------------------------------------

Small interfering RNAs (siRNAs) specific for *PRMT5* (si*PRMT5*), si*PRMT5*-1, 5′-CAGCCACUGAUGGACAAUCUGGAAU-3′ and si*PRMT5*-2, 5′-CCGGCUACUUUGAGACUGUGCUUUA-3′ (Hokkaido System Science, Sapporo, Japan) were used to transfect HLE and HuH7 cells that express relatively high levels of *PRMT5*. AccuTarget Negative Control siRNA fluorescein-labeled (Cosmo Bio Co., Ltd., Tokyo, Japan) served as a control nontargeting siRNA (siControl). HLE and HuH7 cells (4×10^5^ and 2×10^6^ cells/dish, respectively) were seeded into 10 cm dishes containing 10 ml of antibiotic-free DMEM with 10% FBS, and were transfected with 400 pmol of siControl or si*PRMT5*-1 and 2 in the presence of 40-*μ*l LipoTrust EX Oligo (Hokkaido System Science) 24 h after cell seeding. After 72 h incubation following siRNA transfection, total RNA and protein were extracted, and cells were treated with EDTA-trypsin and used for functional assays.

Cell proliferation assay
------------------------

The proliferation of HLE and HuH7 cells was evaluated using a Premix WST-1 Cell Proliferation assay system (Takara Bio Inc., Kusatsu, Japan). After transfection of si*PRMT5*, HLE and HuH7 (3×10^3^ cells/well) cells were seeded into 96-well plates in DMEM containing 2% FBS. The optical density of each well was measured 1 h after the addition of 10 *μ*l of WST-1 0, 1 and 3 days after seeding ([@b23-ijo-50-02-0381]). The growth rate indicated an incremental rate of the optical density from the cell seeding day.

Cell invasion assay
-------------------

The ability of cells to invade Matrigel was determined using BioCoat Matrigel invasion chambers (BD Biosciences, Bedford, MA, USA) according to the manufacturer\'s protocol. HLE and HuH7 cells (2.5×10^3^ cells/well) were suspended in serum-free DMEM and seeded in the upper chamber. After an appropriate incubation time, cells present on the surface of the membrane were fixed, stained and counted using a microscope in eight randomly selected fields ([@b24-ijo-50-02-0381]).

Wound healing assay
-------------------

The migration of HLE and HuH7 cells was determined using a wound-healing assay. After transfection, HLE (2×10^4^ cells/well) and HuH7 (5×10^4^ cells/well) were seeded into each well of a 35 mm dish with culture insert (Ibidi GmbH, Martinsried, Germany) in DMEM containing 2% FBS. After 24 h, the insert was removed, and the width of the wound was measured at 100-*μ*m intervals (20/well, ×40 magnification) at cell-dependent time intervals.

Statistical analysis
--------------------

Differences between data of two groups were evaluated using the Mann-Whitney test. The χ^2^ test was used to analyze the significance of the association between the expression levels of *PRMT5* mRNA and the patient clinicopathological parameters. Overall survival rates were calculated using the Kaplan-Meier method, and the differences in survival curves were evaluated using the log-rank test. All statistical analyses were performed using JMP 10 software (SAS Institute Inc., Cary, NC, USA). A p-value \<0.05 was considered statistically significant.

Results
=======

Expression of PRMT5 in HCC cell lines
-------------------------------------

The levels of *PRMT5* mRNA differed among the nine HCC cell lines regardless of their differentiated phenotypes ([Fig. 1A](#f1-ijo-50-02-0381){ref-type="fig"}). HuH7 (differentiated) and HLE (undifferentiated) cells expressed relatively high levels of *PRMT5* mRNA and were used in the functional analyses described below. As shown in [Fig. 1B](#f1-ijo-50-02-0381){ref-type="fig"}, PRMT5 protein was distributed in the cytoplasm, especially in the perinuclear compartment.

Effects of inhibiting PRMT5 expression
--------------------------------------

The specificity of si*PRMT5*s were checked using BLAST in the NCCI database ([@b25-ijo-50-02-0381]). Then, the total scores and E-values of the two si*PRMT5*s were 50.1 and 5e^−6^, and the query cover rates of transcriptomes other than *PRMT5* mRNA were \<70%. The knockdown effects of si*PRMT5*-1 and 2 were determined by qRT-PCR and western blot analysis ([Fig. 2A](#f2-ijo-50-02-0381){ref-type="fig"}). The knockdown effect by single si*PRMT5* sequence was not enough for functional analysis, we transfected HCC cells with both the si*PRMT5*s in following analysis. To determine the functions of *PRMT5* in HCC, we used HLE and HuH7 cells transfected with si*PRMT5*-1 and -2 sequences for evaluation of the proliferation, invasion, and migration. In HuH7 cells, *PRMT5* knockdown significantly decreased cell proliferation on days 1 and 3 compared with the untransfected and siControl groups ([Fig. 2B](#f2-ijo-50-02-0381){ref-type="fig"}). Second, the number of cells that invaded Matrigel markedly decreased when *PRMT5* expression was inhibited ([Fig. 3A](#f3-ijo-50-02-0381){ref-type="fig"}). Third, the migration of HuH7 cells decreased significantly after transfection with the si*PRMT5* compared with the untransfected and siControl-transfected cells at 16 and 24 h ([Fig. 3B](#f3-ijo-50-02-0381){ref-type="fig"}). Similarly, invasion and migration of HLE cells were markedly reduced in si*PRMT5*-transfected cells (data not shown).

Patient characteristics
-----------------------

The ages of the 144 patients ranged from 34 to 84 years (median, 65.5 years), the male-to-female ratio was 121:23, and 37 and 80 patients were infected with hepatitis B or C virus, respectively. The numbers of patients with normal liver function, chronic hepatitis and cirrhosis were 10, 82 and 52, respectively. The median duration of patient follow-up was 40.1 months (range, 2.3--145 months); 90, 37 and 17 patients were diagnosed with stage I, II or III HCC, respectively.

Clinical implications of PRMT5 expression levels
------------------------------------------------

There were no significant differences in *PRMT5* mRNA levels in noncancerous tissue samples from patients with normal liver function, chronic hepatitis, and cirrhosis. In contrast, the mean level of *PRMT5* mRNA in HCC tissues was significantly higher compared with that of the corresponding noncancerous tissues (p=0.001) ([Fig. 4A](#f4-ijo-50-02-0381){ref-type="fig"}). When patients were divided according to TNM stage, *PRMT5* mRNA expression levels in patients with stage III HCC were significantly higher compared with patients with stage II HCC ([Fig. 4B](#f4-ijo-50-02-0381){ref-type="fig"}).

To evaluate the prognostic significance of *PRMT5* expression, patients were categorized into low- and high-*PRMT5* groups (n=72 each) according to their median levels of *PRMT5* mRNA expression in HCC tissue described in Materials and methods. High levels of *PRMT5* mRNA were significantly associated with advanced TNM stage, independent of background liver status, tumor size or vascular invasion ([Table I](#tI-ijo-50-02-0381){ref-type="table"}). The members of the high-*PRMT5* group were more likely to have a worse prognosis compared with those in the low *PRMT5* group (5-year overall survival rates, 53 and 76%, respectively; p=0.021) ([Fig. 4C](#f4-ijo-50-02-0381){ref-type="fig"}). However, there were no significant differences between the groups in relapse-free survival rate, and high levels of *PRMT5* were not an independent prognostic factor in multivariate analysis.

Discussion
==========

In the present study, we investigated the function and expression of *PRMT5*. We show here that *PRMT5* mRNA was differentially expressed among HCC cell lines, and that PRMT5 protein was expressed mainly at the cytoplasm of HCC cells. Inhibition of *PRMT5* expression in HCC cell lines using a *PRMT5*-specific siRNA decreased not only the proliferation and migration was reported in a previous study ([@b15-ijo-50-02-0381]), but also invasiveness. These findings suggest that *PRMT5* contributes to the pathogenesis of HCC.

Post-translational protein modification is involved at all levels of cellular regulation. PRMTs catalyze the addition of methyl groups to the guanidinium nitrogen atoms of arginine amino acid residues. *PRMT5* is a type II arginine methyltransferase that catalyzes the symmetric dimethylation of the arginine residues of the histone proteins H3 and H4, which alters chromatin structure to promote the inhibition of the transcription of target genes ([@b7-ijo-50-02-0381],[@b8-ijo-50-02-0381],[@b13-ijo-50-02-0381]). These modifications play an important role in cell differentiation and tumor cell growth. *PRMT5* promotes tumor progression by stimulating cell cycle progression as well as inhibiting proliferation and apoptosis ([@b12-ijo-50-02-0381],[@b14-ijo-50-02-0381],[@b26-ijo-50-02-0381]). Moreover, *PRMT5* plays an important role in stem cell maintenance through its suppression of genes that control differentiation ([@b7-ijo-50-02-0381],[@b12-ijo-50-02-0381],[@b27-ijo-50-02-0381]).

*PRMT5* acts as an oncogene in ovarian cancer, glioblastoma, colorectal cancer, and lung cancer, and *PRMT5* interacts with many other genes ([@b10-ijo-50-02-0381]--[@b14-ijo-50-02-0381],[@b28-ijo-50-02-0381]). *PRMT5* methylates histone residues H3R8 and H4R3 to induce silencing of tumor suppressor genes such as *ST7* and *NM23* ([@b8-ijo-50-02-0381]). Further, *PRMT5* contributes to diverse cellular functions through its interactions with E2F-1, IL-2, cyclin E1, the CDK4 complex, and E-cadherin ([@b28-ijo-50-02-0381]--[@b30-ijo-50-02-0381]). In particular, the inhibitory function of *PRMT5* on signaling pathways that inhibit the activities of p53 and the TRAIL receptors may represent important mechanisms underlying its putative oncogenic activities ([@b8-ijo-50-02-0381]). From these previous studies, it can be speculated that high *PRMT5* expression was associated with an elevated proliferation ability of HCC cells via an apoptosis restraint through suppression of p53, TRAIL receptors and E2F-1 ([@b8-ijo-50-02-0381],[@b29-ijo-50-02-0381],[@b30-ijo-50-02-0381]). Increased migration and invasion abilities of tumor cells by overexpression of *PRMT5* may be attributed to suppression of E-cadherin ([@b7-ijo-50-02-0381]). Further analyses of *PRMT5*-related pathways will be desirable to elucidate molecular mechanisms of *PRMT5* in HCC.

Although the mean level of *PRMT5* mRNA was significantly higher in HCC tissues compared with those of the corresponding noncancerous tissues, it was independent of chronic inflammation and hepatic fibrosis, suggesting that suppression of *PRMT5* expression may represent a specific event that occurs in the final stage of the initiation of HCC. Zhang *et al* showed that patients with high expression of PRMT5 protein in cytoplasm had shorter survival duration in the cohort with 54 HCC cases ([@b15-ijo-50-02-0381]). Our results also indicated that high expression of PRMT5 mRNA contributed to worse prognosis. It is important that the influence of PRMT5 expression level on patient prognosis was consistent with another large cohort. Consistent with the results of our functional analyses, high levels of *PRMT5* expression in HCC tissues were an adverse prognostic factor after curative hepatectomy. Further, higher levels of *PRMT5* mRNA were significantly associated with advanced disease stage.

Taken together, our findings suggest that analysis of *PRMT5* expression will enhance the clinical management of HCC. For example, determining the levels of *PRMT5* mRNA in liver biopsies or resected tissues will facilitate risk stratification of patients with HCC and may serve as a criterion for determining the most appropriate therapy tailored for individual patients. Moreover, our findings show promise for developing new therapies for HCC that employ small molecules, and antibodies, or both targeting *PRMT5* expression, and activity. Further research on signaling pathways that act through or are regulated by *PRMT5* may reveal other targets for the treatment of HCC.

The present study has certain limitations. Overexpression experiments of PRMT5 and global expression analyses of proteins that potentially interact with *PRMT5* as well as apoptosis assays will be required for further understanding of the biological functions of *PRMT5* in HCC. External validation of the reproducibility of the expression analyses and their standardization across laboratories are required as well. Further, this study was limited by the relatively small sample size.

Our results indicate that *PRMT5* plays oncogenic roles in HCC by enhancing the malignant phenotype of tumor cells, though further analysis are required for clarifying the specific mechanism of PRMT5 in HCC. PRMT5 shows promise as a biomarker for patient stratification and is a potential target of molecular therapy in HCC.

![Analysis of the expression and function of *PRMT5* in HCC cell lines. (A) The levels of *PRMT5* mRNA in HCC cell lines according to their differentiated phenotypes. (B) Immunofluorescence staining for PRMT5 protein in HCC cell lines.](IJO-50-02-0381-g00){#f1-ijo-50-02-0381}

![Confirmation of knockdown of PRMT5 expression and function of PRMT5 in HCC cell lines. (A) qRT-PCR and western blot analysis to confirm the activity of *PRMT5* siRNAs. (B) Cell proliferation assay of HuH7 cells. The *PRMT5*-specific siRNA significantly decreased cell growth. ^\*^p\<0.05.](IJO-50-02-0381-g01){#f2-ijo-50-02-0381}

![Phenotypes of HuH7 cells transfected with a *PRMT5*-specific siRNA. Knockdown of *PRMT5* expression inhibited the invasiveness (A) and migration (B) of HCC cells. ^\*^P\<0.05.](IJO-50-02-0381-g02){#f3-ijo-50-02-0381}

![Expression of *PRMT5* mRNA in resected tissues. (A) There were no significant differences of *PRMT5* mRNA levels among noncancerous tissues categorized according to the status of the background uninvolved liver. *PRMT5* mRNA was expressed at higher levels in HCC tissues compared with the corresponding noncancerous tissues. NS, not significant. (B) Analysis of *PRMT5* mRNA levels as a function of HCC stage. (C) Patients with HCC with high levels of *PRMT5* expressions experienced significantly shorter overall survival.](IJO-50-02-0381-g03){#f4-ijo-50-02-0381}

###### 

Association between expression levels of *PRMT5* mRNA and clinicopathological parameters in 144 patients with hepatocellular carcinoma (HCC).

  Clinicopathological parameters   High *PRMT5* group (n=72)   Low *PRMT5* group (n=72)   p-value
  -------------------------------- --------------------------- -------------------------- -----------------------------------------------------
  Age (years)                                                                             0.615
   \<65 year                       31                          34                         
   ≥65 year                        41                          38                         
  Gender                                                                                  0.254
   Male                            58                          63                         
   Female                          14                          9                          
  Background liver                                                                        0.391
   Normal liver                    6                           4                          
   Chronic hepatitis               37                          45                         
   Cirrhosis                       29                          23                         
  Pugh-Child\'s classification                                                            0.511
   A                               68                          66                         
   B                               4                           6                          
  Hepatitis virus                                                                         0.558
   Absent                          14                          13                         
   HBV                             21                          16                         
   HCV                             37                          43                         
  AFP (ng/ml)                                                                             1.000
   ≤20                             39                          39                         
   \>20                            33                          33                         
  PIVKA II (mAU/ml)                                                                       0.497
   ≤40                             31                          27                         
   \>40                            41                          45                         
  Tumor multiplicity                                                                      0.228
   Solitary                        53                          59                         
   Multiple                        19                          13                         
  Tumor size                                                                              0.475
   \<3.0 cm                        25                          21                         
   ≥3.0 cm                         47                          51                         
  Differentiation                                                                         0.079
   Well                            22                          13                         
   Moderate to poor                50                          59                         
  Growth type                                                                             0.370
   Expansive growth                58                          62                         
   Invasive growth                 14                          10                         
  Serosal infiltration                                                                    0.331
   Absent                          57                          52                         
   Present                         15                          20                         
  Formation of capsule                                                                    0.213
   Absent                          27                          20                         
   Present                         45                          52                         
  Infiltration to capsule                                                                 0.503
   Absent                          35                          31                         
   Present                         37                          41                         
  Septum formation                                                                        0.484
   Absent                          23                          27                         
   Present                         49                          45                         
  Vascular invasion                                                                       0.122
   Absent                          50                          58                         
   Present                         22                          14                         
  UICC pathological stage                                                                 0.012[a](#tfn1-ijo-50-02-0381){ref-type="table-fn"}
   I                               42                          48                         
   II                              16                          21                         
   III                             14                          3                          

Statistically significant difference (p\<0.05). HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, α-fetoprotein; PIVKA, protein induced by vitamin K antagonists; UICC, Union for International Cancer Control.
